RxDoctor Payments Data

Hao Huang, MD

Internal Medicine · Cranston, RINPI 1902826316

Payments from drug & device makers

$607in general payments, 2019–2025

Across 20 payments — averaging $30.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Astellas Pharma US Inc$298
  • Otsuka America Pharmaceutical, Inc.$220
  • Sunovion Pharmaceuticals Inc.$89

What the payments were for

  • Food & beverage$34457%
  • Education$26343%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$607 in reported general payments places this provider in the 75th percentile of 808 internal medicine providers in Rhode Island.

See all internal medicine providers in Rhode Island

Medicare billing

Part B allowed, 2024
$258,841
Medicare patients
546
Services billed
2,863

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban1,665$485,750
JardianceEmpagliflozin304$92,090
TrulicityDulaglutide58$49,308
BiktarvyBictegrav/Emtricit/Tenofov Ala11$46,460
EntrestoSacubitril/Valsartan135$45,562
Trelegy ElliptaFluticasone/Umeclidin/Vilanter74$45,454
Atorvastatin Calcium2,101$41,984
TradjentaLinagliptin161$41,481
ArexvyRsvpref3 Antigen/As01e/Pf123$37,790
MyrbetriqMirabegron164$37,423
Breo ElliptaFluticasone/Vilanterol84$36,877
Trazodone Hcl1,915$33,637
NuplazidPimavanserin Tartrate13$31,451
Invega SustennaPaliperidone Palmitate12$31,006
OzempicSemaglutide29$30,274

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq$298$37,423164 claims
Otsuka America Pharmaceutical, Inc.Rexulti$220$18,89430 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 808 internal medicine providers in Rhode Island.

Other internal medicine in Cranston

See the full list for Rhode Island

Where these figures come from

Is this you, or does something look wrong? →